IP Library › Granted Patent US 12,728,111
Granted Patent B2
US 12,728,111 · App. 18/009,935 · Granted Sep 8, 2026

Electrophilic compounds and electrophilic prodrugs for treating aneurysm

Inventors: Francisco J. Schopfer (Pittsburgh, PA); Bruce A. Freeman (Pittsburgh, PA); Yang Zhao (Ann Arbor, MI); Yuqing E. Chen (Superior Township, MI); Jifeng Zhang (Ann Arbor, MI)
Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education; The Regents of the University of Michigan
A61K31/231A61P9/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,728,111
App. No.
18/009,935
Granted
Sep 8, 2026
Kind
B2
Abstract

A method comprising administering to a subject having an aneurysm, suspected of having an aneurysm, or at risk of developing an aneurysm, a therapeutically effective amount of a compound selected from (i) a nitroalkene fatty acid, (ii) an unsaturated fatty acid having an electron withdrawing group, a leaving group, and a carbon-carbon double bond disposed between the electron withdrawing group and the leaving group, (iii) a thiolated nitro fatty acid, (iv) a dicarboxylic acid compound containing an electron withdrawing group, or a mixture of at least two of (i)-(iv).

Claims (7)

1 . A method of treating an aneurysm, comprising administering to a subject a therapeutically effective amount of 10-nitro-octadec-9-enoic acid.

2 . The method of claim 1 , wherein the aneurysm is an aortic aneurysm.

3 . The method of claim 1 , wherein the aneurysm is a vascular aneurysm.

4 . The method of claim 2 , wherein the aortic aneurysm is an abdominal aortic aneurysm.

5 . The method of claim 2 , wherein the aortic aneurysm is a thoracic aortic aneurysm or a thoracoabdominal aortic aneurysm.

6 . The method of claim 1 , wherein the aneurysm is an intracranial aneurysm.

7 . The method of claim 1 , wherein the aneurysm is an aneurysm of celiac artery, mesenteric artery, renal arteries, splenic artery, hepatic artery, iliac arteries, femoral artery, popliteal artery or any branch of the aorta.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2022
From: SCHOPFER, FRANCISCO J.; FREEMAN, BRUCE A.
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 062060/0158 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2022
From: ZHAO, YANG; CHEN, YUQING E.; ZHANG, JIFENG
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 062060/0170 →
Continuity (2)
Provisional Application 63042707 · Jun 23, 2020
Related Publication 20230241019A1 · Aug 3, 2023
References Cited (35)
US 8324277B2 · Freeman · 2012 [cited by applicant]
US 9066902B2 · Freeman et al. · 2015 [cited by applicant]
US 10213417B2 · Freeman et al. · 2019 [cited by applicant]
US 10744106B2 · Freeman et al. · 2020 [cited by applicant]
US 10751310B2 · Freeman et al. · 2020 [cited by applicant]
US 10765652B2 · Fazzari et al. · 2020 [cited by applicant]
US 10835518B2 · Freeman et al. · 2020 [cited by applicant]
US 11491128B2 · Fazzari et al. · 2022 [cited by applicant]
US 20110039935A1 · Pierzynowski · 2011 [cited by applicant]
US 20140099354A1 · Dietz et al. · 2014 [cited by applicant]
US 20200101036A1 · Ogawa et al. · 2020 [cited by applicant]
US 20220040134A1 · Freeman et al. · 2022 [cited by applicant]
WO WO2005073164A1 · 2005 [cited by applicant]
WO WO2018067709 · 2018 [cited by applicant]
WO WO2020081957A1 · 2020 [cited by applicant]
WO WO2021188448A1 · 2021 [cited by applicant]
WO WO2022040222A1 · 2022 [cited by applicant]
Cleveland Clinic, https://my.clevelandclinic.org/health/diseases/22769-aneurysm, 2022 (Year: 2022). [cited by examiner]
Nettersheim et al., Cardiovasc Res. Jul. 20, 2022;118(9) :2211-2225 (Year: 2022). [cited by examiner]
Zhao, Cardiovasc Drugs Ther. Jul. 15, 2021;35(5):939-951 (Year: 2021). [cited by examiner]
Ambrozova, Biochimica et Biophysica Acta, 2016 (Year: 2016). [cited by examiner]
ROM, Curr Opin Lipidol 2020 (Year: 2020). [cited by examiner]
Yanbo, National Institutes of Health, 2020 (Year: 2020). [cited by examiner]
Shen (Year: 2014) -Interv Neuroradiol. Jul.-Aug. 2014;20(4):442-7. [cited by examiner]
Gao (Year: 2023), Signal transduction and Targeted Therapy, 2023. [cited by examiner]
Wang et al. (Scientific Reports vol. 4, Article No. 4905, 2014) (Year: 2014). [cited by examiner]
Tousoulis (International Journal of Cardiology, vol. 165, Issue 2, May 10, 2013, 213-216). (Year: 2013). [cited by examiner]
International Search Report and Written Opinion issued for International Application No. PCT/US2021/028175 on Aug. 11, 2021. [cited by applicant]
Office Action issued in Japanese Patent Application No. 2022-579739, dated Apr. 11, 2025, English Translation. [cited by applicant]
Robledinos-Anton et al., “Activators and Inhibitors of NRF2: A Review of Their Potential Clinical Development,” [cited by applicant]
Shi et al., “Nrf-2 signaling inhibits intracranial aneurysm formation and progression by modulating vascular smooth muscle cell phenotype and function,” [cited by applicant]
Cui et al., “Nitrated Fatty Acids: Endogenous Anti-inflammatory Signaling Mediators,” [cited by applicant]
Extended European Search Report for European Application No. 21828888.4, dated Jun. 10, 2024, 13 pages. [cited by applicant]
Zhao et al., “Suppression of Vascular Macrophage Activation by Nitro-Oleic Acid and its Implication for Abdominal Aortic Aneurysm Therapy,” [cited by applicant]
Final Office Action, dated Dec. 15, 2025, issued in corresponding Japan Application No. 2022-579739. 3 pages. [cited by applicant]